Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Gemigliptin/Rosuvastatin FDC vs Coadministration
NCT02670070Phase 1Unknown
- Sponsor
- LG Chem
- Start
- Mar 2016
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gemigliptin and rosuvastatin in type 2 diabetes mellitus (T2DM) and dyslipidemia (2 arms), sponsored by LG Chem. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Status: unknown.
02
Drugs
gemigliptinrosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT02670070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670070.